Cevira®

Cevira® – breakthrough technology for the treatment of persistent oncogenic HPV and precancerous lesions of the cervix.

Cevira® is in development as a treatment for cervical persistent oncogenic human papilloma virus (HPV) infections and precancerous lesions. The treatment is based on our highly selective Photocure Technology® combining a photosensitizer with activation by light of a specific wavelength. It consists of a convenient, fully integrated drug delivery and light device to be applied intravaginally by the gynecologist. The patient can leave the physician office immediately and go back to daily activities and easily remove the device when the treatment is completed.
Selectively targeting the diseased area, Cevira® is a treatment modality aiming to preserve the competence of the cervix, an improvement over surgical procedures frequently used today.

 

Cevira® treatment is administered locally to the cervix by the gynecologist, using the Cevira drug delivery device. After the application the patient may return to normal daily activities. The device includes an integrated light source that automatically starts and stops photoactivation of the drug. The device is easily removed by the patient when the treatment is completed.

Cevira® has the potential to serve a high unmet medical need

Patients with persistent oncogenic HPV infections and low grade squamous intraepithelial cervical lesions (LSIL, CIN1) lack available treatments and are referred to tedious gynecological examinations and follow-up. This causes patient distress due to the risk of disease progression, and Cevira® may be an excellent treatment alternative in these patients.
For patients with high grade squamous intraepithelial lesions (HSIL, CIN2/3), common surgical procedures (e.g. LEEP, cold knife conization) are associated with increased risk of undesirable side effects including bleeding, infection, scarring (stenosis), infertility and complications in later pregnancies with risk of pre-term delivery.
Cevira® has demonstrated statistically significant efficacy and safety in patients with HSIL, which has over 1 mill cases diagnosed annually in the US and EU, and might be an excellent first line treatment for these patients for several reasons:

  • Non-invasive, targeted treatment of HPV infection and precancerous lesions
  • Preserving cervical function
  • Only local, transient self-limiting side effects
  • Fewer monitoring visits to the gynecologist
  • Easy and convenient procedure for both gynecologist and patient